Physician Payment Data is Where the Action Is
Look beyond the EHR incentive program. A national effort to turn CMS's recent release of Medicare physician payment data into useful, actionable data visualizations is the hottest HIT challenge right now.
FDA Advisory Committee Votes Against Moxduo Approval
- QRxPharma (ASX: QRX and OTCQX: QRXPY)
announced today that the United States Food and Drug Administration (FDA) Anesthetic and
Analgesic Drug Products Advisory Committee has voted to recommend against approval of Moxduo,
an immediate release Dual Opioid® for the treatment of moderate to severe acute pain. The Advisory
Committee found the Company did not provide sufficient evidence to warrant approval of Moxduo at
Waiting For Medicaid To Kick In
Nearly 2 million Californians have gained coverage with the expansion of the Medi-Cal program for poor and disabled people, including those who transitioned from temporary programs like Healthy Way LA. But roughly 800,000 more applications are pending from people presumed to be eligible for the program.
Looking at Costs and Risks, Many Skip Health Insurance
A poll of uninsured people in December found that of those who did not plan to get coverage, half said that cost was the main reason. Nearly 3 in 10 said they objected to the government’s requiring it, while about one in 10 said they felt they did not need it.
MiR-21 as a Prognostic Factor for NSCLC
MicroRNA (miR)-21 has been revealed as an oncogene in cancer development, and is one of the miRNAs closely connected to angiogenesis. The authors aimed to explore the impact of miR-21 expression in both tumor and stromal compartments of non-small cell lung cancer (NSCLC), and correlations between miR-21 and angiogenic protein markers.
Eli Lilly's Cyramza Approved for Stomach Cancer
The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach.
Gentic Variant for Difficult-to-Treat Invasive Lobular Carcinoma Identified
The discovery of the genetic variant, in conjunction with other markers, could help in the development of future genetic screening tools to assess women's risk of developing invasive lobular cancer, and also gives researchers important new clues about the genetic causes of the disease and a related precursor to cancer called lobular carcinoma in situ.
HIX Enrollment Closed, Risk Assignment Challenges Start
The Obama administration is boasting that 8 million Americans, including a good number of young people, have enrolled in public exchange plans. The big question now is how will new members fit into the risk adjustment puzzle?
Deal Volume Dips While Value Soars in First Quarter
Across the country, a historically fragmented hospital market is organizing around a select group of for-profit and not-for-profit systems. And that means competition has increased for fewer acquisition targets that still remain on the market.
Give ACOs a break, AHA tells CMS Innovation Center
The American Hospital Association is lobbying the CMS Innovation Center to make it easier for accountable care organizations to earn Medicare bonuses and delay potential penalties as the agency looks to expand the initiative.
Consumption of Processed Meat May Increase the Risk of Colorectal Cancer in Some
Dietary factors, including meat, fruits, vegetables and fiber, are associated with colorectal cancer; however, there is limited information as to whether these dietary factors interact with genetic variants to modify risk of colorectal cancer. In this study, the authors conducted genome-wide association studies between genetic variants, diet, and the susceptibility to colorectal cancer.
AstraZeneca and Pfizer Collaborate on a New Oncology Trial Design
Drug giants AstraZeneca and Pfizer are working on a new clinical trial design, to be launched in Britain in July or August of this year, to include multiple drugs for evaluation in a single trial. This is expected to be both time and cost saving and could significantly hasten drug development.